Molecular Partners AG, a biotechnology company, engages in the discovery and development of Designed Ankyrin Repeat Proteins (DARPins) based on the designed repeat protein technology. The company focuses on therapeutic, diagnostic, and biotechnological applications of DARPins. DARPins are binding proteins that show activity against various disease targets, including cell surface receptors, cytokines, proteases, kinases, and viral coat proteins. The company was incorporated in 2004 and is based in Zurich, Switzerland.
Current Team (4)Update
Funding Rounds (2) - $59.8MUpdate
Venture capital in Life Sciences and IT
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that...
Venture capital subsidiary
Index Ventures is a multi-stage international venture capital firm with deep sector expertise...
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since...